Accidental administration of the remifentanil formulation Ultiva™ into the epidural space and the complete time course of its consequences: a case report

BACKGROUND: Ultiva™ contains the potent short-acting μ-opioid receptor agonist remifentanil hydrochloride, and it is commonly administered intravenously during general anesthesia. It is not approved for epidural or intrathecal use in clinical practice because it contains glycine as an acidic buffer....

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimoto, Kota, Sakamoto, Sachiyo, Mikami, Makiko, Hirota, Kiichi, Shingu, Koh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818778/
https://www.ncbi.nlm.nih.gov/pubmed/29497674
http://dx.doi.org/10.1186/s40981-016-0046-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818778/
https://www.ncbi.nlm.nih.gov/pubmed/29497674
http://dx.doi.org/10.1186/s40981-016-0046-5

Ejemplares similares